Gary K. Lee

CIK: 0001907345

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (64.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (35.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LYEL

Lyell Immunopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

LYEL
Lyell Immunopharma, Inc.
Aug 21, 2026
Sale(S)
Direct
1.5K shares at avg. $15.54$23K
LYEL
Lyell Immunopharma, Inc.
Aug 10, 2026
Sale(S)
Direct
131 shares at avg. $14.34$2K
LYEL
Lyell Immunopharma, Inc.
May 11, 2026
Sale(S)
Direct
130 shares at avg. $18.92$2K
LYEL
Lyell Immunopharma, Inc.
Feb 11, 2026
Sale(S)
Direct
1.7K shares at avg. $23.39$39K
LYEL
Lyell Immunopharma, Inc.
Feb 10, 2026
Award(A)
Option (right to buy)
Direct
50K shares-
LYEL
Lyell Immunopharma, Inc.
Feb 10, 2026
Sale(S)
Direct
147 shares at avg. $23.12$3K
LYEL
Lyell Immunopharma, Inc.
Feb 9, 2026
Award(A)
Direct
4K shares-
LYEL
Lyell Immunopharma, Inc.
Nov 10, 2025
Sale(S)
Direct
138 shares at avg. $16.16$2K
LYEL
Lyell Immunopharma, Inc.
Oct 27, 2025
Award(A)
Option (right to buy)
Direct
68K shares-
LYEL
Lyell Immunopharma, Inc.
Aug 21, 2025
Sale(S)
Direct
1.5K shares at avg. $10.54$15K
LYEL
Lyell Immunopharma, Inc.
Aug 20, 2025
Award(A)
Direct
8K shares-
LYEL
Lyell Immunopharma, Inc.
Aug 12, 2025
Sale(S)
Direct
136 shares at avg. $10.34$1K
LYEL
Lyell Immunopharma, Inc.
Aug 11, 2025
Sale(S)
Direct
131 shares at avg. $10.53$1K
LYEL
Lyell Immunopharma, Inc.
Feb 10, 2025
Award(A)
Direct
112.5K shares-

		Type	Shares	Price		Ownership
Aug 21, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	1,457	$15.54	$22,642	Direct
Aug 10, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	131	$14.34	$1,879	Direct
May 11, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	130	$18.92	$2,460	Direct
Feb 11, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	1,671	$23.39	$39,085	Direct
Feb 10, 2026	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	50,000	-	-	Direct
Feb 10, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	147	$23.12	$3,399	Direct
Feb 9, 2026	LYEL Lyell Immunopharma, Inc.	Award(A)	4,000	-	$0	Direct
Nov 10, 2025	LYEL Lyell Immunopharma, Inc.	Sale(S)	138	$16.16	$2,230	Direct
Oct 27, 2025	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	68,000	-	-	Direct
Aug 21, 2025	LYEL Lyell Immunopharma, Inc.	Sale(S)	1,453	$10.54	$15,320	Direct
Aug 20, 2025	LYEL Lyell Immunopharma, Inc.	Award(A)	8,000	-	-	Direct
Aug 12, 2025	LYEL Lyell Immunopharma, Inc.	Sale(S)	136	$10.34	$1,406	Direct
Aug 11, 2025	LYEL Lyell Immunopharma, Inc.	Sale(S)	131	$10.53	$1,379	Direct
Feb 10, 2025	LYEL Lyell Immunopharma, Inc.	Award(A)	112,500	-	-	Direct

1-14 of 14 transactions

About Lee Gary K.

Lee Gary K. (SEC CIK 0001907345) files insider reports with the SEC as Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL).

Signal8 holds 10 ownership filings by Lee Gary K., all Form 4s, filed between Feb 26, 2025 and Aug 25, 2026. Those filings report 14 transactions, from Feb 10, 2025 to Aug 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lee Gary K.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Lee Gary K.

Aug 21, 2026: Open-market sale of LYEL shares (Form 4, code S).
Aug 10, 2026: Open-market sale of LYEL shares (Form 4, code S).
May 11, 2026: Open-market sale of LYEL shares (Form 4, code S).
Feb 11, 2026: Open-market sale of LYEL shares (Form 4, code S).
Feb 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).

Other insiders filing for Lyell Immunopharma, Inc. (LYEL)

Aguirre Jarrad Mattieu, Chief Medical Officer
Shook David, Chief Medical Officer
Seely Lynn, President and CEO
Hill Stephen J., Chief Operating Officer
Bulis Veronica Sanchez, VP, Corporate Controller
Innovative Cellular Therapeutics Holdings Ltd, 10% Owner

How to read Form 4 transaction codes